Ysios Capital, the Spanish venture capital firm, has appointed Thomas Harth as principal to help the group source and evaluate investment opportunities. Mr Harth joins from Gimv NV, the Belgium-based investment group, where he managed early-stage life science investments. At Gimv, he co-led investments in Anjarium Biosciences, a genetic medicines company, and Kinaset Therapeutics, a respiratory therapeutics concern. He was also involved in the management of portfolio companies including Breath Therapeutics which was acquired by the Italian pharma company Zambon SpA in 2019. Mr Harth holds a master’s degree in bioengineering and applied economics from the University of Gent, Belgium.
Ysios Capital announced the appointment on 4 March 2022.
Copyright 2022 Evernow Publishing Ltd